172 related articles for article (PubMed ID: 25375004)
1. Evolving and expanding treatment options in NSCLC.
Knoop T
Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):13-4. PubMed ID: 25375004
[No Abstract] [Full Text] [Related]
2. Contemporary issues in NSCLC.
Walker S
Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):14-5. PubMed ID: 25375005
[No Abstract] [Full Text] [Related]
3. Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.
Brown NA; Aisner DL; Oxnard GR
Am Soc Clin Oncol Educ Book; 2018 May; 38():708-715. PubMed ID: 30231309
[TBL] [Abstract][Full Text] [Related]
4. Review of treatment options for oligometastatic non-small cell lung cancer.
Folkert MR; Timmerman R
Clin Adv Hematol Oncol; 2015 Mar; 13(3):186-93. PubMed ID: 26352427
[TBL] [Abstract][Full Text] [Related]
5. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
7. Evolving Treatment Options for Lung Cancer.
Morgensztern D; Herbst RS
Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
[No Abstract] [Full Text] [Related]
8. The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective.
Young K; da Cunha Santos G; Card P; Leighl N
Cancer Cytopathol; 2019 Feb; 127(2):72-78. PubMed ID: 30512242
[No Abstract] [Full Text] [Related]
9. Editorial: Individualizing treatment of nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2020 Jan; 32(1):35-36. PubMed ID: 31652144
[No Abstract] [Full Text] [Related]
10. Management of early-stage non-small-cell lung cancer (NSCLC).
Le Chevalier T
Eur J Cancer; 2011 Sep; 47 Suppl 3():S292-3. PubMed ID: 21943988
[No Abstract] [Full Text] [Related]
11. Combined modality treatment of lung cancer (NSCLC and SCLC).
Delbaldo C; Le Péchoux C; Le Chevalier T
Cancer Chemother Biol Response Modif; 2002; 20():677-95. PubMed ID: 12703230
[No Abstract] [Full Text] [Related]
12. [Treatment options in the elderly patients with advanced non-small-cell lung cancer].
Li K; Chen J
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):721-4. PubMed ID: 26813588
[No Abstract] [Full Text] [Related]
13. Neoplastic pulmonary cytology: why all the fuss over "NSCLC"?
Cohen MB; Weydert JA
Cancer Cytopathol; 2011 Feb; 119(1):3-4. PubMed ID: 21319309
[No Abstract] [Full Text] [Related]
14. [MANAGEMENT OF NON-SMALL CELL LUNG CANCER].
Sibille A; Paulus A; Martin M; Bourhaba M; Barthélemy N; Radermecker M; Corhay JL; Louis R; Duysinx B
Rev Med Liege; 2015 Sep; 70(9):432-41. PubMed ID: 26638443
[TBL] [Abstract][Full Text] [Related]
15. Management of non-small cell lung cancer in the era of personalized medicine.
Rocco G; Morabito A; Leone A; Muto P; Fiore F; Budillon A
Int J Biochem Cell Biol; 2016 Sep; 78():173-179. PubMed ID: 27425397
[TBL] [Abstract][Full Text] [Related]
16. Mind-mapping for lung cancer: towards a personalized therapeutics approach.
Mollberg N; Surati M; Demchuk C; Fathi R; Salama AK; Husain AN; Hensing T; Salgia R
Adv Ther; 2011 Mar; 28(3):173-94. PubMed ID: 21337123
[TBL] [Abstract][Full Text] [Related]
17. Non-small cell lung cancer: One size doesn't fit all.
Leung L; Lam KC; Mok TS
Asia Pac J Clin Oncol; 2012 Sep; 8(3):211-2. PubMed ID: 22913780
[No Abstract] [Full Text] [Related]
18. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
Santarpia M; Altavilla G; Pitini V; Rosell R
Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
[TBL] [Abstract][Full Text] [Related]
19. [Management of non-small-cell lung carcinoma (NSCLC) of stage III B].
Koukourakis M
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S33-6. PubMed ID: 11924241
[No Abstract] [Full Text] [Related]
20. The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?
De Ruysscher D; Vansteenkiste J; Belderbos J; Decaluwé H; Dingemans AM
J Thorac Oncol; 2016 Mar; 11(3):284-6. PubMed ID: 26922920
[No Abstract] [Full Text] [Related]
[Next] [New Search]
